Ahmet Demirkazık

Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.

Nasser H. Hanna, R. Kaiser, Richard N. Sullivan et al. · Journal of Clinical Oncology · 2013 · 83 citations

Medicine, Oncology, Pharmacology +16

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

F. Li, smail �elik, Nuri Faruk Aykan et al. · Cancer · 1998 · 36 citations

Medicine, Oncology, Pharmacotherapy +10

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Nir Peled, Roni Gillis, Patrizia Froesch et al. · Lung Cancer · 2020 · 33 citations

Medicine, Oncology, Pharmacology +13

Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Zsolt Markóczy, Veronika Sárosi, Iveta Kudaba et al. · BMC Cancer · 2018 · 28 citations · Full text

Medicine, Oncology, Pharmacology +17

Modification and Implementation of NCCN Guidelines™ on Non–Small Cell Lung Cancer in the Middle East and North Africa Region

Abdul Rahman Jazieh, Hanaa Bamefleh, Ahmet Demirkazık et al. · Journal of the National Comprehensive Cancer Network · 2010 · 24 citations · Full text

Medicine, Oncology, Radiation Oncology +10